Shares of Sarepta Therapeutics fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator’s request to pause all shipments of its gene therapy Elevidys in the United States.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets